Nurix Therapeutics, Inc. $NRIX Shares Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC boosted its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 32.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,095 shares of the company’s stock after purchasing an additional 3,988 shares during the quarter. Hsbc Holdings PLC’s holdings in Nurix Therapeutics were worth $189,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in NRIX. GF Fund Management CO. LTD. acquired a new position in Nurix Therapeutics in the fourth quarter worth $28,000. Exchange Traded Concepts LLC boosted its holdings in shares of Nurix Therapeutics by 38.9% during the first quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company’s stock valued at $109,000 after acquiring an additional 2,562 shares during the period. E Fund Management Co. Ltd. acquired a new position in shares of Nurix Therapeutics during the first quarter valued at $122,000. BNP Paribas Financial Markets acquired a new position in shares of Nurix Therapeutics during the fourth quarter valued at $164,000. Finally, GAMMA Investing LLC boosted its holdings in shares of Nurix Therapeutics by 202.2% during the first quarter. GAMMA Investing LLC now owns 14,018 shares of the company’s stock valued at $167,000 after acquiring an additional 9,380 shares during the period.

Nurix Therapeutics Stock Up 8.7%

NRIX stock opened at $9.91 on Friday. The company has a market capitalization of $757.62 million, a P/E ratio of -3.80 and a beta of 2.10. The company has a 50-day simple moving average of $10.95 and a 200 day simple moving average of $11.53. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.27. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. The business had revenue of $44.06 million during the quarter, compared to the consensus estimate of $16.26 million. Equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Analysts Set New Price Targets

NRIX has been the subject of several analyst reports. Stephens reissued an “overweight” rating and set a $30.00 price target on shares of Nurix Therapeutics in a report on Thursday, July 10th. UBS Group reduced their price target on shares of Nurix Therapeutics from $30.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, July 10th. Baird R W raised shares of Nurix Therapeutics to a “strong-buy” rating in a report on Tuesday, August 26th. Morgan Stanley set a $16.00 price target on shares of Nurix Therapeutics and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Finally, HC Wainwright reduced their price target on shares of Nurix Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a report on Monday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $29.07.

Insider Activity

In other Nurix Therapeutics news, insider Gwenn Hansen sold 4,308 shares of the business’s stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total value of $51,739.08. Following the sale, the insider directly owned 69,023 shares in the company, valued at approximately $828,966.23. The trade was a 5.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 5,402 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $11.03, for a total transaction of $59,584.06. Following the completion of the sale, the chief financial officer owned 35,512 shares in the company, valued at approximately $391,697.36. This trade represents a 13.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 14,014 shares of company stock worth $163,014. 7.40% of the stock is owned by company insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.